Mometasonfuroaat Basic Pharma (Mometasone Furoate Monohydrate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene transcription to suppress inflammatory cytokines, reduce leukocyte infiltration, and decrease vascular permeability, which together diminish swelling and mucus production.

The appropriate dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

Enquiries can be submitted via the product page on gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with lower‑potency agents such as fluticasone, it may achieve symptom control with a similar or lower dosing frequency, but choice of therapy should be individualized by the prescriber.

Store the nasal spray at room temperature, below 25 °C, in the original packaging. Protect it from moisture, direct sunlight and extreme temperatures to maintain product stability.

The product is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into each nostril, and spray the prescribed number of sprays while breathing in gently.

Serious but rare risks include nasal septal perforation, cataract or glaucoma development with long‑term use, adrenal suppression, and severe allergic reactions such as anaphylaxis. Patients should report any unusual symptoms to their healthcare provider promptly.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid use. Caution is also advised for patients with active untreated infections of the nasal mucosa, recent nasal surgery, or those who require systemic corticosteroid therapy.